Reexamining Chronic Toxoplasma gondii Infection: Surprising Activity for a “Dormant” Parasite
- 428 Downloads
Purpose of Review
Despite over a third of the world’s population being chronically infected with Toxoplasma gondii, little is known about this largely asymptomatic phase of infection. This stage is mediated in vivo by bradyzoites within tissue cysts. The absence of overt symptoms has been attributed to the dormancy of bradyzoites. In this review, we reexamine the conventional view of chronic toxoplasmosis in light of emerging evidence challenging both the nature of dormancy and the consequences of infection in the CNS.
New and emerging data reveal a previously unrecognized level of physiological and replicative capacity of bradyzoites within tissue cysts. These findings have emerged in the context of a reexamination of the chronic infection in the brain that correlates with changes in neuronal architecture, neurochemistry, and behavior that suggest that the chronic infection is not without consequence.
The emerging data driven by the development of new approaches to study the progression of chronic toxoplasma infection reveals significant physiological and replicative capacity for what has been viewed as a dormant state. The emergence of bradyzoite and tissue cyst biology from what was viewed as a physiological “black box” offers exciting new areas for investigation with direct implications on the approaches to drug development targeting this drug-refractory state. In addition, new insights from studies on the neurobiology on chronic infection reveal a complex and dynamic interplay between the parasite, brain microenvironment, and the immune response that results in the detente that promotes the life-long persistence of the parasite in the host.
KeywordsToxoplasma Tissue cyst Bradyzoite Glycosylation CNS infection
Preparation of this article was supported in part by NIH/NIAID R21AI122894 awarded to APS and IDeA award from NIH/NIGMS 5P30GM110787 (COBRE for the Center for Molecular Medicine. PI Louis B Hersh, University of Kentucky) project awarded jointly to APS and MSG.
Compliance of Ethical Standards
Conflict of Interest
Matthew Gentry, Anthony Sinai, Animesh Dhara, Elizabeth Watts, Abhijit Patwardhan, and Robert Murphy declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 16.White MW, Radke JR, Radke JB. Toxoplasma development-turn the switch on or off? Cellular microbiology. 2014.Google Scholar
- 18.•Pittman KJ, Aliota MT, Knoll LJ. Dual transcriptional profiling of mice and Toxoplasma gondii during acute and chronic infection. BMC Genomics. 2014;15:806. The use of RNASeq to simultaneously establish the interplay between parasite and host at the level of gene expression hold the promise of dissecting the complex interplay during different stages of the chronic infection.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Knoll LJ, Tomita T, Weiss LM. Bradyzoite Development In: Weiss LM, Kim K, editors. Toxoplasma gondii The Model Apicomplexan: Perspectives and Methods 2nd Edition ed. London, United Kingdom: Academic Press (Elsevier); 2014. p. 521-49.Google Scholar
- 21.••Watts E, Zhao Y, Dhara A, Eller B, Patwardhan A, Sinai AP. Novel Approaches Reveal that Toxoplasma gondii Bradyzoites within Tissue Cysts Are Dynamic and Replicating Entities In Vivo. mBio. 2015;6(5):e01155–15. This work conclusively dispels the notion that parasite replication does not occur during the chronic phase of infection. The work reveals that bradyzoites within cysts are not uniform and that the properties of tissue cysts vary during the course of infection. Quantification of bradyzoites within tissue cysts vastly reveals an unappreciated level of complexity in the progression of chronic toxoplasmosis.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Cummings RD, Etzler ME. Antibodies and Lectins in Glycan Analysis. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzo CR, et al., editors. Essentials of Glycobiology 2nd edition. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2008. p. 633-49.Google Scholar
- 32.••Tomita T, Bzik DJ, Ma YF, Fox BA, Markillie LM, Taylor RC, et al. The Toxoplasma gondii Cyst Wall Protein CST1 Is Critical for Cyst Wall Integrity and Promotes Bradyzoite Persistence. PLoS Pathog. 2013;9(12):e1003823. Identification of the primary protein target responsible for lectin lableling of the cyst wall also establishes TgCST1 as a key strutural element in the mantaining cyst integrity.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Tomita T, Tatsuki T, Yakubu R, Tu V, Ma YF, Weiss LM. Making home sweet and sturdy: Toxoplasma gondii ppGalNAc-ts glycosylate in heirarchical order and confer cyst wall rigidity..mBio. 2016;Submitted.Google Scholar
- 34.•Caffaro CE, Koshy AA, Liu L, Zeiner GM, Hirschberg CB, Boothroyd JC. A nucleotide sugar transporter involved in glycosylation of the Toxoplasma tissue cyst wall is required for efficient persistence of bradyzoites. PLoS Pathog. 2013;9(5):e1003331. Confirms the central role for glycoslylation in the maintenance of chronic toxoplasma infections.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.•Nazarova LA, Ochoa RJ, Jones KA, Morrissette NS, Prescher JA. Extracellular Toxoplasma gondii tachyzoites metabolize and incorporate unnatural sugars into cellular proteins. Microbes and infection/Institut Pasteur. 2016;18(3):199–210. This technical advance is the first use of chemical biology approaches to identify glycoproteins in Toxoplasma.CrossRefGoogle Scholar
- 41.Guerardel Y, Leleu D, Coppin A, Lienard L, Slomianny C, Strecker G, et al. Amylopectin biogenesis and characterization in the protozoan parasite Toxoplasma gondii, the intracellular development of which is restricted in the HepG2 cell line. Microbes Infect/Institut Pasteur. 2005;7(1):41–8.CrossRefGoogle Scholar
- 42.••Uboldi AD, McCoy JM, Blume M, Gerlic M, Ferguson DJ, Dagley LF, et al. Regulation of Starch Stores by a Ca(2+)-Dependent Protein Kinase Is Essential for Viable Cyst Development in Toxoplasma gondii. Cell Host Microbe. 2015;18(6):670–81. This work demonstrates that the dysregualtion of amylopectin metabolism is lethal to bradyzoites and promotes the clearance of tissue cysts. It demonstrates that amylopectin must play a role in bradyzoites rather than serve merely as an energy storage system for rapid growth following reactivation. This presents amylopecting metabolism as a potential drug target in chronic toxoplasmosis.CrossRefPubMedGoogle Scholar
- 51.••Dubey JP, Ferreira LR, Alsaad M, Verma SK, Alves DA, Holland GN, et al. Experimental Toxoplasmosis in Rats Induced Orally with Eleven Strains of Toxoplasma gondii of Seven Genotypes: Tissue Tropism, Tissue Cyst Size, Neural Lesions, Tissue Cyst Rupture without Reactivation, and Ocular Lesions. PloS One. 2016;11(5):e0156255. This comprehensive study and review of the literature in rats and mice presents the simialrites and differences in these model rodent systems. Given the body of behavioral work in rats, the revisiting of the rat infection model will be useful for the integration of future behavioral studies.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Van Der Waaij D. Formation, growth and multiplication of Toxoplasma gondii cysts in mouse brain. Trop Georg Med. 1959;11:345–60.Google Scholar
- 54.Hooshyar H, Rostamkhani P, Arbabi M. Study on growth of Toxoplasma gondii tissue cyst in laboratory mouse. Jundishpur J Microbiol. 2009;2(4):140–3.Google Scholar
- 58.Sutterland AL, Fond G, Kuin A, Koeter MW, Lutter R, van Gool T, et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta psychiatrica Scandinavica. 2015.Google Scholar
- 60.Mahami-Oskouei M, Hamidi F, Talebi M, Farhoudi M, Taheraghdam AA, Kazemi T, et al. Toxoplasmosis and Alzheimer: can Toxoplasma gondii really be introduced as a risk factor in etiology of Alzheimer? Parasitol Res. 2016.Google Scholar
- 73.Hermes G, Ajioka JW, Kelly KA, Mui E, Roberts F, Kasza K, et al. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation. 2008;5:48.CrossRefPubMedPubMedCentralGoogle Scholar
- 74.Melzer TC, Cranston HJ, Weiss LM, Halonen SK. Host Cell Preference of Toxoplasma gondii Cysts in Murine Brain: A Confocal Study. J Neuroparasitology. 2010;1.Google Scholar
- 79.•Gaskell EA, Smith JE, Pinney JW, Westhead DR, McConkey GA. A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PloS One. 2009;4(3):e4801. The potential for direct inteference with dopamine metabolism establishes a potential mechanism for parasite mediated modulation of CNS function.CrossRefPubMedPubMedCentralGoogle Scholar
- 81.•Brooks JM, Carrillo GL, Su J, Lindsay DS, Fox MA, Blader IJ. Toxoplasma gondii Infections Alter GABAergic Synapses and Signaling in the Central Nervous System. mBio. 2015;6(6):e01428–15. Exposition of infection mediated neurological changes and their association with structural changes in GABAergic responses begins to examine the basis for potential paasrite driven changes during chronic infection.CrossRefPubMedPubMedCentralGoogle Scholar
- 82.••David CN, Frias ES, Szu JI, Vieira PA, Hubbard JA, Lovelace J, et al. GLT-1-Dependent Disruption of CNS Glutamate Homeostasis and Neuronal Function by the Protozoan Parasite Toxoplasma gondii. PLoS Pathogens. 2016;12(6):e1005643. This study is important in that it not only describes the changes instituted in the infected mouse brain but also provides a mechansitic framework supported by biochemical data in addition to quantitative moprhometry to document infection-related changes in the brain.CrossRefPubMedPubMedCentralGoogle Scholar
- 93.••Doggett JS, Nilsen A, Forquer I, Wegmann KW, Jones-Brando L, Yolken RH, et al. Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc Nat Acad Sci USA. 2012;109(39):15936–41. The first family of drugs that exhibit signficant efficacy in the clearance of tissue cysts in the mouse model. The study also provides valuable insights into the metabolic and physiological state of bradyzoites supporting a view for their being more active than previously considered.CrossRefPubMedPubMedCentralGoogle Scholar
- 95.•Benmerzouga I, Checkley LA, Ferdig MT, Arrizabalaga G, Wek RC, Sullivan Jr WJ. Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis. Antimicrob Agents Chemother. 2015;59(11):6939–45. The establishment of translational control as a potential target for drug dvelopment. The study also highlights the utility of drug repurposing as a strategy to streamline drug dvelopment for what may be considered orphan infections.CrossRefPubMedPubMedCentralGoogle Scholar
- 96.•Vidadala RS, Rivas KL, Ojo KK, Hulverson MA, Zambriski JA, Bruzual I, et al. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis. J Med Chem. 2016;59(13):6531–46. Identification of TgCDPK’s as targets for drug development against chronic toxoplasma infections presents an additional and legitimate target. The development of an orally available compound holds promise for treatment.CrossRefPubMedGoogle Scholar